Tenon Medical to Release 2025 Financial Results on March 19, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Source: PRnewswire
Tenon Medical Inc. saw a significant price increase of 20.93% in pre-market trading as it crossed above its 5-day SMA.
The company announced that its fourth quarter 2025 revenue is projected to be between $1.45 million and $1.48 million, indicating approximately 90% year-over-year growth. Additionally, full year 2025 revenue is expected to range from $3.91 million to $3.94 million, reflecting a year-over-year growth of about 20%. This strong financial outlook, along with the upcoming earnings release scheduled for March 19, 2026, has contributed to positive investor sentiment.
This anticipated financial performance highlights Tenon Medical's robust development and increasing market demand in the medical device sector, particularly following the launch of the Catamaran SI Joint Fusion System.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNON
Wall Street analysts forecast TNON stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.326
Low
2.50
Averages
2.75
High
3.00
Current: 0.326
Low
2.50
Averages
2.75
High
3.00
About TNON
Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenon Receives FDA Clearance for Catamaran SI Joint Fusion System
- FDA Clearance Update: Tenon Medical has received FDA 510(k) clearance for its updated Catamaran® SI Joint Fusion System, which includes various instrument upgrades and reclassification of certain disposable instruments to reusable status, expected to significantly lower per-procedure costs, thereby enhancing the company's gross margins and cash flow.
- Economic Benefit Enhancement: By transitioning disposable instruments to reusable ones, Tenon anticipates reduced capital expenditures and logistical costs, a strategic improvement that will directly drive the company's financial health and strengthen its competitive position in the medical device market.
- Market Adoption Progress: Since the national launch of the Catamaran system in October 2022, over 1,500 Catamaran fixation devices have been implanted in patients across the United States, indicating strong market demand for the product in treating sacroiliac joint disruptions and degenerative sacroiliitis.
- Commitment to Continuous Innovation: Tenon's CEO Steven M. Foster stated that this clearance reflects the company's ongoing commitment to refining the Catamaran system, aimed at providing better treatment experiences for physicians and patients while laying the foundation for sustainable growth.
See More
Tenon Medical Completes $4.2 Million Public Offering
- Funding Amount: Tenon Medical successfully completed a public offering raising $4.2 million, issuing 11,052,631 shares of common stock and 13,263,159 common stock purchase warrants, demonstrating the company's capital market capabilities.
- Use of Proceeds: The funds will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, aiming to enhance market competitiveness and product coverage.
- Warrant Details: Each common stock warrant can be exercised at an exercise price of $0.38 per share and is immediately exercisable, which increases investor participation and market liquidity.
- Legal Compliance: The offering is conducted under SEC registration statements, ensuring compliance and laying a foundation for future fundraising activities, reflecting the company's commitment to transparency and regulatory adherence.
See More
Tenon Medical Prices Public Offering for $4.2 Million
- Offering Size and Price: Tenon Medical announced a public offering of up to 11,052,631 shares at a price of $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's active engagement in capital markets and financing capabilities.
- Diverse Use of Proceeds: The funds raised will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which aims to enhance market competitiveness and customer service capabilities.
- Legal and Underwriting Support: WallachBeth Capital LLC serves as the sole placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Sheppard, Mullin, Richter & Hampton LLP provide legal counsel to the company and the placement agent, ensuring compliance and smooth execution of the offering process.
- Future Outlook and Risks: Tenon Medical indicated that future revenues and developments will be influenced by various factors; while the current financing activity provides necessary funding, attention must be paid to market changes and potential risks.
See More
Tenon Medical Prices $4.2M Public Offering
- Offering Pricing: Tenon Medical announced a public offering priced at $0.38 per share for up to 11.05 million common shares and accompanying warrants, aiming to raise $4.2 million before placement agent fees and other expenses, indicating the company's ability to access capital markets.
- Clear Use of Proceeds: The funds will be utilized to partially repay outstanding convertible notes, expand commercial operations, support R&D, increase inventory capacity, and fund working capital and other general corporate purposes, reflecting strategic financial management.
- Negative Market Reaction: Despite successfully pricing the offering, the company's shares fell by 12.79%, indicating a negative market response to the financing plan, which could impact investor confidence and future fundraising capabilities.
- Future Development Plans: Tenon Medical plans to fully launch SImmetry+ in the second half of 2026 and targets Alpha for a third approach in Q4 2026, demonstrating the company's proactive strategy in product development and market expansion.
See More
Tenon Medical Prices $4.2 Million Public Offering
- Offering Size: Tenon Medical has priced a public offering of up to 11,052,631 shares at $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's ability to access capital markets effectively.
- Use of Proceeds: The net proceeds from this offering will be allocated towards repaying outstanding convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which is expected to enhance market competitiveness and customer service capabilities.
- Legal Compliance: WallachBeth Capital LLC acts as the sole placement agent for this offering, ensuring compliance and market trust, while also indicating the company's diligence in legal matters.
- Investor Information: Tenon Medical will conduct this offering under SEC registration statements, ensuring transparency and providing necessary legal protections for investors, thereby boosting market confidence in its future growth prospects.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
Tenon Receives FDA Clearance for Catamaran SI Joint Fusion System
- FDA Clearance Update: Tenon Medical has received FDA 510(k) clearance for its updated Catamaran® SI Joint Fusion System, which includes various instrument upgrades and reclassification of certain disposable instruments to reusable status, expected to significantly lower per-procedure costs, thereby enhancing the company's gross margins and cash flow.
- Economic Benefit Enhancement: By transitioning disposable instruments to reusable ones, Tenon anticipates reduced capital expenditures and logistical costs, a strategic improvement that will directly drive the company's financial health and strengthen its competitive position in the medical device market.
- Market Adoption Progress: Since the national launch of the Catamaran system in October 2022, over 1,500 Catamaran fixation devices have been implanted in patients across the United States, indicating strong market demand for the product in treating sacroiliac joint disruptions and degenerative sacroiliitis.
- Commitment to Continuous Innovation: Tenon's CEO Steven M. Foster stated that this clearance reflects the company's ongoing commitment to refining the Catamaran system, aimed at providing better treatment experiences for physicians and patients while laying the foundation for sustainable growth.
See More
Tenon Medical Completes $4.2 Million Public Offering
- Funding Amount: Tenon Medical successfully completed a public offering raising $4.2 million, issuing 11,052,631 shares of common stock and 13,263,159 common stock purchase warrants, demonstrating the company's capital market capabilities.
- Use of Proceeds: The funds will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, aiming to enhance market competitiveness and product coverage.
- Warrant Details: Each common stock warrant can be exercised at an exercise price of $0.38 per share and is immediately exercisable, which increases investor participation and market liquidity.
- Legal Compliance: The offering is conducted under SEC registration statements, ensuring compliance and laying a foundation for future fundraising activities, reflecting the company's commitment to transparency and regulatory adherence.
See More
Tenon Medical Prices Public Offering for $4.2 Million
- Offering Size and Price: Tenon Medical announced a public offering of up to 11,052,631 shares at a price of $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's active engagement in capital markets and financing capabilities.
- Diverse Use of Proceeds: The funds raised will be allocated for repaying convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which aims to enhance market competitiveness and customer service capabilities.
- Legal and Underwriting Support: WallachBeth Capital LLC serves as the sole placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Sheppard, Mullin, Richter & Hampton LLP provide legal counsel to the company and the placement agent, ensuring compliance and smooth execution of the offering process.
- Future Outlook and Risks: Tenon Medical indicated that future revenues and developments will be influenced by various factors; while the current financing activity provides necessary funding, attention must be paid to market changes and potential risks.
See More
Tenon Medical Prices $4.2M Public Offering
- Offering Pricing: Tenon Medical announced a public offering priced at $0.38 per share for up to 11.05 million common shares and accompanying warrants, aiming to raise $4.2 million before placement agent fees and other expenses, indicating the company's ability to access capital markets.
- Clear Use of Proceeds: The funds will be utilized to partially repay outstanding convertible notes, expand commercial operations, support R&D, increase inventory capacity, and fund working capital and other general corporate purposes, reflecting strategic financial management.
- Negative Market Reaction: Despite successfully pricing the offering, the company's shares fell by 12.79%, indicating a negative market response to the financing plan, which could impact investor confidence and future fundraising capabilities.
- Future Development Plans: Tenon Medical plans to fully launch SImmetry+ in the second half of 2026 and targets Alpha for a third approach in Q4 2026, demonstrating the company's proactive strategy in product development and market expansion.
See More
Tenon Medical Prices $4.2 Million Public Offering
- Offering Size: Tenon Medical has priced a public offering of up to 11,052,631 shares at $0.38 per share, aiming for approximately $4.2 million in gross proceeds, reflecting the company's ability to access capital markets effectively.
- Use of Proceeds: The net proceeds from this offering will be allocated towards repaying outstanding convertible notes, expanding the commercial footprint of its product portfolio, training clinicians, and hiring additional sales representatives, which is expected to enhance market competitiveness and customer service capabilities.
- Legal Compliance: WallachBeth Capital LLC acts as the sole placement agent for this offering, ensuring compliance and market trust, while also indicating the company's diligence in legal matters.
- Investor Information: Tenon Medical will conduct this offering under SEC registration statements, ensuring transparency and providing necessary legal protections for investors, thereby boosting market confidence in its future growth prospects.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
